Tocilizumab In Severe To Critical Confirmed COVID-19: A Case Series At Ulin Referral Hospital Of South Kalimantan

Authors

  • Haryati Haryati Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Lambung Mangkurat University/Ulin Hospital, Banjarmasin, South Kalimantan, Indonesia
  • Fidya Rahmadhany Arganita Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Lambung Mangkurat University/Ulin Hospital, Banjarmasin, South Kalimantan, Indonesia
  • Widya Ramadhaniati Resident of Pulmonology and Respiratory Medicine, Faculty of Medicine, Lambung Mangkurat University/Ulin Hospital, Banjarmasin, South Kalimantan, Indonesia

DOI:

https://doi.org/10.33533/jpm.v15i1.2862

Keywords:

COVID-19, CRP, Interleukin-6, Tocilizumab

Abstract

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a new type of coronavirus that causes pneumonia. The clinical severity of COVID-19 is related to the presence of a “cytokine storm” that causes overproduction of inflammatory mediators such as interleukin (IL)-6. Tocilizumab (TCZ) as an IL-6 inhibitor is subject of major studies as a potential therapeutic agent. This study reported 20 cases of COVID-19 patients being treated with the IL-6 inhibitor TCZ beside standard therapy. Patients were followed up on clinical, laboratory and chest x-rays before and after the administration of therapy which were report descriptively. The oxygen saturation of patients who survived shows rapid improvements. The laboratory results showed that CRP decreased after administration TCZ immediately. Meanwhile, other markers improve slowly, such as leucocytes, Neutrophyl Lymphocyte Ratio (NLR), Absolute Lymphocyte Count (ALC) and Lactate Dehydrogenase (LDH) but ferritin was tended to fluctuate. In chest X-ray’s, infiltrate bilateral on admission began to diminished until almost disappeared on the 14th day after TCZ. From 20 patients, 80% of patients survived with improvement in clinical, laboratory and chest X-rays, while the rest death with a good response on first therapy but fluctuated and worsened before death. Tocilizumab can be considered to provide clinical improvements in severe and critical COVID-19 patients.

References

World Health Organization. WHO Coronavirus (COVID-19) Dashboard [Internet]. 2021 [cited 2021 May 3]. Available from: https://covid19.who.int/?bot=1

Erlina Burhan, Fathiyah Isbaniah, Agus Dwi Susanto TY, Aditama, Soedarsono, Teguh Rahayu Sartono, Yani Jane Sugiri R, Tantular, Bintang YM Sinaga, R.R Diah Handayani HA. Buku Penumonia COVID-19 Diagnosis & Penatalaksanaan di Indonesia. 2020.

Badan Informasi Geospasial. Indonesia COVID-19 Map [Internet]. [cited 2021 May 6]. Available from: https://covid19.big.go.id/

Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment [Internet]. Vol. 39, Clinical Rheumatology. Springer; 2020 [cited 2021 May 7]. p. 2085–94. Available from: /pmc/articles/PMC7260446/

Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: A meta-analysis [Internet]. Vol. 92, Journal of Medical Virology. John Wiley and Sons Inc; 2020 [cited 2021 May 7]. p. 2283–5. Available from: /pmc/articles/PMC7267383/

Atal S, Fatima Z. IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy? Pharmaceut Med [Internet]. 2020 Aug 1 [cited 2021 May 3];34(4):223–31. Available from: https://doi.org/10.1007/s40290-020-00342-z

Bohn MK, Hall A, Sepiashvili L, Jung B, Steele S, Adeli K. Pathophysiology of COVID-19: Mechanisms underlying disease severity and progression [Internet]. Vol. 35, Physiology. American Physiological Society; 2020 [cited 2021 May 3]. p. 288–301. Available from: /pmc/articles/PMC7426542/

Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. [cited 2021 May 5]; Available from: www.pnas.org/cgi/doi/10.1073/pnas.2005615117

Kewan T, Covut F, Al–Jaghbeer MJ, Rose L, Gopalakrishna K V., Akbik B. Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study. EClinicalMedicine. 2020;24.

Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A [Internet]. 2020 May 19 [cited 2021 May 4];117(20):10970–5. Available from: https://pubmed.ncbi.nlm.nih.gov/32350134/

Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020;383(24):2333–44.

Wagner J, DuPont A, Larson S, Cash B, Farooq A. Absolute lymphocyte count is a prognostic marker in Covid-19: A retrospective cohort review. Int J Lab Hematol. 2020 Dec 1;42(6):761–5.

Pimentel GD, Dela MCM, Laviano A. High neutrophil to lymphocyte ratio as a prognostic marker in COVID_19 patients. 2020;(January). Available from: https://doi.org/10.1016/j.clnesp.2020.08.004

Gallo Marin B, Aghagoli G, Lavine K, Yang L, Siff EJ, Chiang SS, et al. Predictors of COVID-19 severity: A literature review. Rev Med Virol. 2021;31(1):1–10.

Wan Y, Shang J, Sun S, Tai W, Chen J, Geng Q, et al. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry VIRUS-CELL INTERACTIONS crossm Downloaded from. jvi.asm.org 1 J Virol [Internet]. 2020;94:2015–34. Available from: http://jvi.asm.org/

Knorr JP, Colomy V, Mauriello CM, Ha S. Tocilizumab in patients with severe COVID‐19: A single‐center observational analysis. J Med Virol [Internet]. 2020 Nov 29 [cited 2021 May 8];92(11):2813–20. Available from: https://onlinelibrary.wiley.com/doi/10.1002/jmv.26191

Han Y, Zhang H, Mu S, Wei W, Jin C, Xue Y, et al. Lactate dehydrogenase, a Risk Factor of Severe COVID-19 Patients: A Retrospective and Observational Study. medRxiv. 2020;12(12):11245–58.

Sepulveda JL. Challenges in routine clinical chemistry analysis [Internet]. Second Edi. Accurate Results in the Clinical Laboratory. Elsevier; 2019. 141–163 p. Available from: http://dx.doi.org/10.1016/B978-0-12-813776-5.00010-8

Poggiali E, Zaino D, Immovilli P, Rovero L, Losi G, Dacrema A, et al. Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients. Clin Chim Acta [Internet]. 2020;509:135–8. Available from: https://doi.org/10.1016/j.cca.2020.06.012

Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Vol. 9, Frontiers in Immunology. Frontiers Media S.A.; 2018.

Keske Ş, Tekin S, Sait B, İrkören P, Kapmaz M, Çimen C, et al. Appropriate use of tocilizumab in COVID-19 infection. Int J Infect Dis [Internet]. 2020 Oct 1 [cited 2021 May 5];99:338–43. Available from: https://doi.org/10.1016/j.ijid.2020.07.036

Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021 Jan 15;

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;

Gómez-Pastora J, Weigand M, Kim J, Wu X, Strayer J, Palmer AF, et al. Hyperferritinemia in critically ill COVID-19 patients – Is ferritin the product of inflammation or a pathogenic mediator? [Internet]. Vol. 509, Clinica Chimica Acta. Elsevier B.V.; 2020 [cited 2021 May 7]. p. 249–51. Available from: /pmc/articles/PMC7306200/

Gomez-Pinedo U, Matias-Guiu J, Laura Márquez-Aguirre A, Yuan J, Bhaskar SonuBhaskar S, Bhaskar S, et al. Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper. Front Immunol | www.frontiersin.org [Internet]. 2020 [cited 2021 May 5];1:1648. Available from: www.frontiersin.org

Huang S, Hu B, Yin L. The cytokine storm and COVID-19. J Med Virol.

Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, et al. On the Alert for Cytokine Storm: Immunopathology in COVID-19. Vol. 72, Arthritis and Rheumatology. John Wiley and Sons Inc.; 2020. p. 1059–63.

Zhang C, Wu Z, Li J-W, Zhao H, Wang G-Q. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents [Internet]. 2020 May;55(5):105954. Available from: https://doi.org/10.1016/j.ijantimicag.2020.105954

Ali A, Kamjani MH, Kesselman MM. The Role of Tocilizumab in Cytokine Storm and Improving Outcomes in COVID-19. Recent Pat Antiinfect Drug Discov. 2020 Sep 23;15(2):104–12.

Downloads

Published

2021-06-10

How to Cite

Haryati, H., Arganita, F. R., & Ramadhaniati, W. (2021). Tocilizumab In Severe To Critical Confirmed COVID-19: A Case Series At Ulin Referral Hospital Of South Kalimantan. Jurnal Profesi Medika : Jurnal Kedokteran Dan Kesehatan, 15(1). https://doi.org/10.33533/jpm.v15i1.2862

Issue

Vol. 15 No. 1 (2021): Jurnal Profesi Medika : Jurnal Kedokteran dan Kesehatan

Section

Article

License

Copyright Notice

All articles submitted by the author and published in the Jurnal Profesi Medika : Jurnal Kedokteran dan Kesehatan, are fully copyrighted by the publication of Jurnal Profesi Medika : Jurnal Kedokteran dan Kesehatan under the Creative Commons Attribution-NonCommercial 4.0 International License by technically filling out the copyright transfer agreement and sending it to the publisher

Note :

The author can include in separate contractual arrangements for the non-exclusive distribution of rich versions of journal publications (for example: posting them to an institutional repository or publishing them in a book), with the acknowledgment of their initial publication in this journal.

Authors are permitted and encouraged to post their work online (for example: in an institutional repository or on their website) before and during the submission process because it can lead to productive exchanges, as well as earlier and more powerful citations of published works. (See Open Access Effects).